On Wednesday, T-Mobile US Inc(NYSE:TMUS)’s shares inclined 0.92% to $39.32.
T-Mobile US, Inc. (TMUS) declared that the quarterly dividend on its 5.50% Mandatory Convertible Preferred Stock (“Preferred Stock”) will be paid on September 15, 2015, to holders of record as of September 1, 2015. The dividend will be paid at a rate of $0.6875 per share of Preferred Stock.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, such as smartphones, tablets, and other mobile communication devices, in addition to accessories, which are manufactured by various suppliers. It offers services, devices, and accessories through its owned and operated retail stores, in addition to through its Websites. +
Geron Corporation (NASDAQ:GERN)’s shares gained 4.10% to $3.05.
Geron Corporation (GERN) stated financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Results
For the second quarter of 2015, the company stated a net loss of $9.4 million, or $0.06 per share, contrast to $8.7 million, or $0.06 per share, for the comparable 2014 period. Revenues for the second quarter of 2015 were $251,000 contrast to $341,000 for the comparable 2014 period. Interest and other income for the second quarter of 2015 amounted to $145,000 contrast to $99,000 for the comparable 2014 period. The company ended the second quarter of 2015 with $157.0 million in cash and investments.
Total operating expenses for the second quarter of 2015 were $9.7 million contrast to $9.0 million for the comparable 2014 period. Research and development expenses for the second quarter of 2015 were $4.8 million contrast to $5.2 million for the comparable 2014 period. General and administrative expenses for the second quarter of 2015 were $4.0 million contrast to $3.9 million for the comparable 2014 period. Operating expenses for the 2015 second quarter also comprised of restructuring charges of $941,000 in connection with the company’s organ
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
At the end of Wednesday’s trade, Forest City Enterprises, Inc. (NYSE:FCE.A)‘s shares dipped -0.05% to $21.00.
Forest City Enterprises, Inc. (NYSE:FCEA ) declared that its Board of Directors has set the date of a special meeting of shareholders in connection with the company’s formerly declared plan to convert to a real estate investment trust (“REIT”). The meeting will be held on October 15, 2015, at 2:00 p.m., Eastern Time. Shareholders of record as of the close of business on August 31, 2015, will be entitled to receive notice of and to vote at the meeting.
Forest City Enterprises, Inc. acquires, owns, develops, and manages commercial and residential real estate and land in the United States. The company’s Commercial group acquires, owns, develops, and operates regional malls, specialty/urban retail centers, office and life science buildings, and mixed-use projects, in addition to operates Barclays Center, a sports and entertainment arena located in Brooklyn, New York. Its Residential group acquires, owns, develops, and operates residential rental properties, counting upscale and middle-market apartments and adaptive re-use developments, in addition to develops and manages military family housing.
Intra-Cellular Therapies Inc (NASDAQ:ITCI), ended its Wednesday’s trading session with 1.03% gain, and closed at $27.35.
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, recently declared its financial results for the quarter ended June 30, 2015, and offered a corporate update.
Second Quarter 2015 Financial Results
Intra-Cellular Therapies (the Company) stated a net loss of $21.5 million, or $(0.61) per share (basic and diluted), for the second quarter of 2015 contrast to a net loss of $4.5 million, or $(0.15) per share (basic and diluted), for the second quarter of 2014.
Research and development (R&D) expenses for the second quarter of 2015 were $17.8 million, contrast to $2.7 million for the second quarter of 2014. The enhance is primarily due to costs associated with the Phase 3 clinical development program for ITI-007 in schizophrenia, which was initiated in late 2014.
General and administrative (G&A) expenses were $4.0 million for the second quarter of 2015, contrast to $2.1 million for the same period in 2014. The enhance is primarily the result of higher stock-based compensation expense and to a lesser extent salaries and professional fees and costs due to the activities associated with being a public company.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression, and other neuropsychiatric and neurological disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
